Narsoplimab
Narsoplimab, sold under the brand name Yartemlea, is a monoclonal antibody used for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Narsoplimab, sold under the brand name Yartemlea, is a monoclonal antibody used for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is a mannan-binding lectin-associated serine protease-2 (MASP-2) inhibitor. It is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody.
Narsoplimab was approved for medical use in the United States in December 2025. The US Food and Drug Administration considers it to be a first-in-class medication.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1365398820 under CC BY-SA 4.0; modifications have been made.